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Abstract
Primary tumors often emerge within genetically altered fields of premalignant cells
that appear histologically normal but have a high chance of progression to malignancy.
Clinical observations have suggested that these premalignant fields pose high risks
for emergence of secondary recurrent tumors if left behind after surgical removal of
the primary tumor. In this work, we develop a spatio-temporal stochastic model of
epithelial carcinogenesis, combining cellular reproduction and death dynamics with a
general framework for multi-stage genetic progression to cancer. Using this model, we
investigate how macroscopic features (e.g. size and geometry of premalignant fields)
depend on microscopic cellular properties of the tissue (e.g. tissue renewal rate, muta-
tion rate, selection advantages conferred by genetic events leading to cancer, etc). We
develop methods to characterize how clinically relevant quantities such as waiting time
until emergence of second field tumors and recurrence risk after tumor resection. We
also study the clonal relatedness of recurrent tumors to primary tumors, and analyze
how these phenomena depend upon specific characteristics of the tissue and cancer
type. This study contributes to a growing literature seeking to obtain a quantitative
understanding of the spatial dynamics in cancer initiation.
1 Introduction
The term ‘field cancerization’ refers to the clinical observation that certain regions of
epithelial tissue have an increased risk for the development of multiple synchronous or
metachronous primary tumors. This term originated in 1953 from repeated observations
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by Slaughter and colleagues of multiple primary oral squamous cell cancers and local re-
currences within a single region of tissue [1]. This phenomenon, also known as the ‘cancer
field effect’ has been documented in many organ systems including head and neck (oral
cavity, oropharynx, and larynx), lung, vulva, esophagus, cervix, breast, skin, colon, and
bladder [2]. Although the exact underlying mechanisms of the field effect in cancer are not
fully understood, recent molecular genetic studies suggest a carcinogenesis model in which
clonal expansion of genetically altered cells (possibly with growth advantages) drives the
formation of a premalignant field [2, 3]. This premalignant field, which may develop in
the form of one or more expanding patches, forms fertile ground for subsequent genetic
transformation events, leading to intermediate cancer fields and eventually clonally diverg-
ing neoplastic growths. The presence of such premalignant fields poses a significant risk
for cancer recurrence and progression even after removal of primary tumors. Importantly,
these fields with genetically altered cells often appear histologically normal and are difficult
to detect; thus, mathematical models to predict the extent and evolution of these fields
may be useful in guiding treatment and prognosis prediction.
In this work we develop and analyze a mathematical model of the cancer field effect.
This model combines spatial cellular reproduction and death dynamics in an epithelial
tissue with a general framework for multi-stage genetic progression to cancer. Using this
model, we investigate how microscopic cellular properties of the tissue (e.g. tissue renewal
rate, mutation rate, selection advantages conferred by genetic events leading to cancer, etc)
impact the process of field cancerization in a tissue. We develop methods to characterize
the waiting time until emergence of second field tumors and recurrence risk after tumor
resection. We also study the clonal relatedness of recurrent tumors to primary tumors by
assessing whether local field recurrences (second field tumors) are more likely than distant
field recurrences (second primary tumors), and analyze how these phenomena depend upon
characteristics of the tissue and cancer type. The methodology developed in this work is
generally applicable to understanding the field effect in many epithelial cancers; in follow-
up work we will calibrate and apply this framework to study recurrence risks due to field
cancerization in specific cancer types.
The current work will contribute to a growing literature on the evolutionary dynamics of
cancer initiation, see e.g. [4–13]. In particular, there have been several previous mathemat-
ical models studying the stochastic evolutionary process of cancer initiation from spatially
structured tissue, e.g. [14–19]. In 1977 Williams and Bjerknes proposed a model of clonal
expansion in epithelial tissue [16]. This model is closely related to the biased voter model
from particle systems theory [20], and in [21, 22] the growth properties and asymptotic
shape of the process were established. Komarova studied a 1-dimensional process with
mutation and showed that the probability of mutant fixation and time to obtain two-hit
mutants differ from the well-mixed setting [14]; this work was generalized to higher dimen-
sions in [19]. Later, in [17,18] the relationships between migration, mutation, selection and
invasion in a spatial stochastic evolutionary model were explored. Martens and colleagues
studied the dynamics of mutation accumulation and population adaptation on a discrete
2
time hexagonal lattice model with nearest neighbor replacement upon reproduction in one
and two dimensions [23, 24]. In a recent work Antal and colleagues consider a stochastic
spatial model of cancer progression where cells acquire successive fitness advantages along
the edge of the tumor. In the context of this model they study the shape of the evolving
tumor front as well as the number of mutations acquired in the tumor [25]. Lastly, in pre-
vious work we studied the accumulation and spread rates of advantageous mutant clones in
a spatially structured population of general dimension [26]. In the current work we build
upon these previous studies to develop a quantitative understanding of field cancerization
and tumor recurrence risks.
The article is organized as follows: in section 2 we introduce the stochastic mathemat-
ical model and describe basic properties regarding the survival and growth rate of mutant
clones. Using previously derived results on the spread of mutant clones, we introduce a
mesoscopic approximation to the model. In section 3 we analyze the model to investigate
the characteristics and extent of local and distant premalignant fields at the time of ini-
tiation. In particular, we determine how the spatial geometry of the field (e.g. number
and size of lesions) depends on cellular and tissue properties such as mutation rate, tissue
renewal rate and mutational fitness advantages. In section 4 we analyze the model to un-
derstand the risk of recurrence due to local or distant field malignancies, as a function of
time and cellular parameters.
Throughout the paper we will use the following notation for the asymptotic behavior
of positive functions,
f(t) ∼ g(t) if f(t)/g(t)→ 1 as t→∞,
f(t) = o(g(t)) or f(t) g(t) if f(t)/g(t)→ 0 as t→∞,
f(t) g(t) if f(t)/g(t)→∞ as t→∞,
f(t) = O(g(t)) if f(t) ≤ Cg(t) for all t,
f(t) = Θ(g(t)) if cg(t) ≤ |f(t)| ≤ Cg(t) for all t.
Finally, we use the notation X =d F to denote that the random variable X has distribution
F .
2 Mathematical framework and basic properties
Cancer initiation is associated with the accumulation of multiple successive genetic or
epigenetic alterations to a cell [27]. A subset of these genetic events may give rise to a
fitness advantage (i.e. an increase in reproductive rate of the cell or avoidance of apoptotic
signals), and subsequently lead to a clonal expansion within the tissue. The expanding
mutant cell populations form the background for further independent genetic events which
lead to carcinogenesis. As a result of this spatial evolutionary process, by the time of cancer
initiation or diagnosis the tissue field surrounding a tumor can be composed of genetically
distinct premalignant lesions of various sizes and stages.
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2.1 Cell-based model
To study the dynamics of this process, we consider a stochastic model which describes the
accumulation and spread of a clone of cells with genetic alterations throughout a spatially
structured tissue (e.g. stratified epithelium). Thus, we consider the model on a regular
lattice Zd ∩ [−L/2, L/2]d, where L > 0 and d is the number of spatial dimensions of the
tissue. Each location in the lattice is occupied by a single cell, and each cell reproduces at
a rate according to its fitness with exponential waiting times. Whenever a cell reproduces,
its offspring replaces one of its 2d lattice neighbors at random, see Figure 1A. The type
of each cell corresponds to its fitness, which is related to the number of genetic hits a
cell has accumulated in a multi-step genetic model of cancer initiation. For example,
type-0 cells have fitness normalized to 1 and are labeled as wild-type or normal (with no
mutations). Initially our entire lattice is occupied by type 0 cells. Type-0 cells acquire the
first mutation at rate u1 to become type-1 cells. The type-1 cell will have a relative fitness
advantage to type-0 cells, given by 1 + s1, for some constant s1 ≥ 0. In general, type-i
cells have a fitness advantage of 1 + si relative to type-(i − 1) cells, and they acquire the
(i+ 1)−th mutation in the sequence at rate ui+1 to become type-(i+ 1) cells. The process
is stopped when a cell develops k mutations; we call this the time of cancer initiation.
The number of mutation k as well as the parameters ui, si for i = 1, . . . , k depend on the
specific cancer type. Although many (epi)genetic events are selectively disadvantageous
(i.e. they confer a selective disadvantage si < 0), the progeny of deleterious mutants die
out quickly so here we restrict our attention to the case si ≥ 0. Note that this process can
be thought of as a spatial version of the Moran process, a spatially well-mixed population
model that is commonly used to describe carcinogenesis (e.g. see [8–12]). In addition, the
spatial reproduction and death dynamics of this model (without mutation) correspond to
the biased voter process which has been well-studied in physics and probability literature.
In fact, a similar voter model approach was previously used to model cellular dynamics
in epithelial tissue and found to correlate well with experimental predictions of clone size
distribution in the mouse epithelium [28].
The total number of cells in the fixed-size population is N ≡ Ld; in most cancer initia-
tion settings this number is quite large (at least 106), while mutation rates are quite small
(orders of magnitude smaller than 1). Therefore we will, unless stated otherwise, restrict
our analysis to regimes where L  1 and ui  1. In Section 2.3, we will briefly discuss
the specific conditions that we impose on the relationship between these parameters. For
mathematical simplicity, the lattice is equipped with periodic boundary conditions; how-
ever in most relevant biological situations the domain size (i.e. cell number) is sufficiently
large so that boundary effects are negligible.
Note on dimension of the model. We analyze the general model in space dimensions
d = 1, 2, 3. While all epithelial tissues have an intrinsically three dimensional architecture,
in some situations considering d = 1, 2 may be a good approximation. For example, cancer
initiation in mammary ducts of the breast, renal tubules of the kidney, and bronchi tubes
4
A" B"
Figure 1: Lattice dynamics. (A) Schematic of spatial Moran model in d = 2: each cell
divides at rate according to its fitness and replaces one of its 2d neighbors: if the light
blue cell divides, its offspring replaces one of the dark blue neighbors, chosen uniformly at
random. Every lattice site is occupied at all times (not shown). (B) Simulation example of
the model: growth of an advantageous clone (light blue) starting from one cell with fitness
advantage s = 0.2 over the surrounding field (dark blue).
of the lung could be viewed as approximately one-dimensional processes, due to the aspect
ratio of tube radius versus length. On the other hand, cancer initiation in the squamous
epithelium of the cervix, the bladder or the oral cavity can be viewed as two-dimensional
process, since initiation occurs in the basal layer of the epithelium which is only 1-2 cells
thick (e.g. see Figure 2). The validity of such approximations poses an interesting problem
in itself, but will not be addressed in this work.
2.2 Survival and growth of a single mutant clone
We first establish some basic behaviors of mutant cells and their clonal progeny within a
tissue. Of particular interest are: (i) the survival probability of a mutant clone, and (ii)
the rate of spatial expansion of the mutant clone through the tissue. In particular, how
are these characteristics influenced by tissue parameters and the cellular fitness advantage
conferred by a mutation? We have addressed some of these questions in a previous work [26]
and restate the results here to make the paper self-contained. In addition, we perform new
simulations in this work to fill in gaps where theoretical results are currently not available.
Consider the probability that a mutant cell survives to form a viable clone (i.e. does not
die out due to demographic stochasticity). Let type-1 cells have fitness 1 + s and type-0
cells have fitness 1, and let φt(x) denote the type of cell at site x in the lattice at time t.
Define
ξt ≡ {x ∈ Zd ∩ [−L/2, L/2]d : φt(x) = 1}.
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Figure 2: Geometry of squamous epithelium. A Basal layer (vertical perspective)
before initiation with local field (left), and after initiation where the tumor is growing
within the local field (right). B Sideways view of the fields before and after initiation,
along the dashed lines in panel A. The proliferative cells inhabiting the two-dimensional
lattice in the model reside in the basal layer of the epithelium. After initiation, malignant
growth is not restricted to basal layer only.
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In other words, ξt is the set of all type-1 cell locations at time t. We initiate the model
with a single type-1 cell at the origin surrounded by type-0 cells in all other locations:
φ0(x) =
{
1, x = 0
0, otherwise,
and assume no further mutations are possible (ui = 0). This simplified model is known as
the Williams-Bjerknes model [16], and if L = ∞ then it corresponds to the biased voter
model, see e.g. [29]. Let |ξt| denote the number of type-1 cells in the model at time t. Then
we can define the extinction time of the process T0 ≡ inf{t > 0 : |ξt| = 0}. The probability
of survival of a single mutant clone with selective advantage s over the surrounding cells is
then the probability of the event {T0 =∞}. By looking at the the process |ξt| only at its
jump times, we note that the embedded process is a discrete time random walk that moves
one up with probability s/(1 + s) or one down with probability 1/(1 + s). This can be
seen by observing that the process only changes at boundaries between type-0 and type-1
cells, and the only possible resulting events are that the type-0 gets replaced by a type-1
(resulting in a jump up in |ξt|) or the type-1 gets replaced by a type-1 (resulting in a jump
down in |ξt|). Analysis of the overall survival probability of this random walk can then be
calculated using simple gambler’s ruin analysis,
P (T0 =∞) = s
1 + s
≈ s,
where the approximation is valid for s  1. Thus, the probability that a mutant clone
with fitness advantage s survives is s1+s , and is independent of the dimension of the tissue.
It is important to understand how the expansion rate of a mutant clone depends on the
selection strength s of the mutant. To this end, we first state a result proven by Bramson
and Griffeath [21,22] which establishes an asymptotic shape for the type-1 clone.
Theorem 2.1 (Bramson and Griffeath). For any ε > 0, there is a tε(ω) such that on
{T0 =∞}
(1− ε)tD ∩ Zd ⊂ ξt ⊂ (1 + ε)tD for t ≥ tε(ω),
where D is a convex set and has the same symmetries as Zd.
In other words, the Bramson-Griffeath shape theorem says that conditional on the clone
never going extinct, the radius of the clone expands linearly. In previous work, we studied
how this linear rate of expansion depends on the selection strength s in the setting of weak
selection strength, see Theorem 1 of [26]. More precisely, if we denote by e1 the first unit
vector in Rd and define the growth rate cd(s) such that
D ∩ {ze1 : z ∈ R} = [−cd(s), cd(s)],
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then as s→ 0,
cd(s) ∼

s d = 1√
4pis/ log(1/s) d = 2√
4β3s d = 3,
(1)
where β3 is the probability that two simple random walks started at 0 and e1 = (1, 0, 0)
never hit. In other words, the radius of the asymptotic shape D approximating the type-1
clone grows linearly with rate on the order of cd(s). Note that as the dimension d increases,
the growth rate increases due to a larger clone boundary size in higher dimensions.
The previous results hold only in the regime of weak selection or small s. For larger
values of the selective advantage s, simulations can be used to obtain cd(s) for d = 2, 3 (in
d = 1 the process can be analyzed directly through simple random walk analysis and we
obtain that c1(s) = s). For example, Figure 3 shows that the s-dependence of the growth
rate is approximately linear for s > 0.5; in this case simple regression yields the estimate
c2(s) ≈ 0.6s + 0.22 (s > 0.5). Thus, a combination of analysis and simulation gives us a
complete picture of how spatial expansion rate of mutant clones in a tissue depend upon
the selective advantage s for a wide range of selection strengths.
0 0.5 1 1.5 2 2.5
0
0.5
1
1.5
s
c 2
(s)
Figure 3: Simulations of clonal expansion rate for large s. Dependence of the
growth rate c2 on the fitness advantage s. Statistics performed on M = 100 samples for
each s-value.
2.3 Approximating with a hybrid mesoscopic model
Our results regarding the survival and growth of a single mutant clone suggest a hybrid
mesoscopic model simplification that enables our analysis of the field cancerization pro-
cess. In particular, each successful mutant clone can be well-approximated as growing
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d-dimensional ball with expansion rate cd(s) as calculated in the previous section. Before
proceeding however, let us clarify the notion of clone ‘survival’ a.k.a. ‘success’ in the full
model, where multiple mutations can arise and compete in the same finite domain. In
particular, we consider a mutant clone with selective advantage s over the background
to be successful if it reaches size  1/s. This criterion guarantees a negligible chance of
extinction in an infinite domain with no interference. In particular, if we define T0 to be
the extinction time of a biased voter model with selective advantage s, one can use the
embedded discrete time process and gambler’s ruin calculations to show that if the biased
voter process reaches k  1/s then P (T0 =∞∣∣|ξ0| = k) ≈ 1− e−ks.
Consider the fate of an unsuccessful type-1 clone arising on a background of type-0 cells.
The clone evolves as a supercritical (s > 1) biased voter model conditioned on extinction.
In [26] we showed that unsuccessful type-1 mutations typically die out by a time of order
`(s) =

s−2 d = 1,
s−1 log (1/s) d = 2,
s−1 d = 3.
(2)
As seen in the previous section, the survival probability in the biased voter model (starting
with a single type 1 cell in a sea of type 0 cells) is s/(1 + s), but in the more complex
spatial Moran model with the possibility of multiple interacting type 1 clones, it is not
immediately clear that this survival probability is still given by s/(1 + s). However, it was
shown in [26] that the above survival probability remains a good approximation as long as
(A0) (1/u1) `(s)(d+2)/2. (3)
If the total number of type-1 cells is always a negligible fraction of N and (A0) holds,
then successful type-1 mutations arrive as a Poisson arrival process with approximate rate
Nu1
s
s+1 , where N is the total number of cells in the tissue. In particular, these conditions
hold for all the numerical examples in this article.
We are now ready to introduce a hybrid mesoscopic model approximation as follows:
Type-1 mutations arrive in the healthy tissue as a Poisson arrival process with rate Nu1,
distributed uniformly at random in the spatial domain. Each mutation event has two
potential outcomes:
• with probability s/(1 + s), the mutation is successful and we approximate the subse-
quent clonal expansion with a ball whose radius grows deterministically. The macro-
scopic growth rate is cd(s), which was derived from individual cellular growth kinetics
as described in section 2.2. As a representative simulation in figure 1B suggests, the
ball in standard L2-norm in Rd will be utilized.
• with probability 1/(1+s), the mutation is unsuccessful, and the clone evolves accord-
ing to the full stochastic (cellular-level) model dynamics conditioned on extinction.
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Note that the remainder of the paper discusses properties of this mesoscopic model.
It will be useful to define γd as the volume of a ball of radius 1 in d dimensions,
γ1 = 2, γ2 = pi, γ3 = 4pi/3.
Note that although the stochastic fluctuations of the shape of expanding clones are lost
in this approximation, one gains generality since the mesoscopic model can approximate a
whole class of microscopic models that admit a shape result in the line of Theorem 2.1.
2.4 Cancer initiation behavior
Although the methodology developed in this work can be generalized to the setting of
k-mutation carcinogenesis models, we will consider for simplicity the classic two-mutation
model of cancer initiation first introduced by Knudson [30]. Here, type-0 cells are wild-type
with fitness 1, type-1 cells are premalignant with fitness 1 + s1 relative to type-0 cells, and
type-2 cells are initiated cancer cells with fitness 1+s2 relative to type-1 cells. The time of
cancer initiation σ2 is defined as the time at which the first successful type-2 cell arrives.
In [26], we studied the situation where s1 = s2 = s > 0 and found that the timing of cancer
initiation is strongly governed by the limiting value of the following meta-parameter:
Γ ≡ (Nu1s)d+1(cddu2s)−1.
Roughly speaking, Γ1/(d+1) represents the ratio of the rate of producing successful type-
1 cells to the subsequent time it take to acquire the first successful type-2. We found
that both the mechanisms and distribution of the cancer initiation time vary significantly
depending on the regime of Γ:
• Regime 1 (R1): When Γ < 1, the first successful type-2 mutation occurs within the
expanding clone of the first successful type-1 mutation (left panel of Figure 4). The
initiation time σ2 is exponential and does not depend on the spatial dimension.
• Regime 2: (R2) For Γ ∈ (10, 100), the first successful type-2 mutation occurs within
one of several successful type-1 clones (middle panel in Figure 4). The initiation time
is no longer exponential and depends explicitly upon the spatial dimension.
• Regime 3 (R3): When Γ > 1000, the first successful type-2 mutation occurs after
many successful type-1 mutations have occurred (right panel of Figure 4). The first
successful type-2 can arise from either a successful or an unsuccessful type-1 family;
the initiation time represents a mixture distribution of these two events.
• Note that for Γ ∈ [1, 10] and Γ ∈ [100, 1000] we say that we are in borderline regimes
R1/R2 and R2/R3 respectively.
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We refer the reader to [26] for mathematical details of these statements. Note that these
‘regimes’ can be thought of as labels highlighting distinct types of initiation behaviors
that arise as Γ changes. In fact the system behavior continuously varies through the
parameter space, and borderline cases between these regimes do exist. Figure 5 shows
how the distribution of the waiting time σ2 varies with changing number of cells N in
d = 2. We note that as N increases, the waiting time distribution shifts to the left and
initiation occurs earlier. By comparing Figures 4 and 5 we see that early initiation times
are associated with a diffuse premalignant field with a large number of independent lesions,
whereas late initiation times are associated with a single premalignant field harboring the
initiating tumor cell.
Regime&1& Regime&2& Regime&3&
Figure 4: The three dynamic regimes. Regime 1: first successful type-2 cell (arrow)
arises in the first premalignant clone, Γ = 0.055. Regime 2: several premalignant clones
are present at the time of the first successful type-2 cell, Γ = 54.47. Regime 3: a large
number of small premalignant clones are present by the time of the first successful type-2
cell, Γ = 5.45× 104. Simulations obtained with parameter values as in Figure 5.
To briefly summarize this section, we have described first a microscopic model of cellular
division, mutation and death within a regularly structured epithelial tissue. Analysis of the
fine-scale dynamics of this model leads to a more tractable hybrid mesoscopic model which
approximates the microscopic model. In a previous work, we studied the time until cancer
initiation (σ2) under this hybrid model and we found three distinct regimes of initiation
behavior in which the distribution of σ2 has distinct parametric forms. In the next section,
we analyze this mesoscopic model to study the characteristics and extent of premalignant
fields at the stochastic time of cancer initiation or diagnosis. In the analyses throughout, we
will consider parameter ranges spanning all three regimes of initiation behavior; however,
for simplicity in regime 3 we will restrict ourselves to the range of parameter space in which
11
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Figure 5: Waiting time until first successful type-2. Cumulative distribution function
(cdf) of σ2, the waiting time until the first successful type-2 mutation, for increasing N
(see Theorem 3.1). Regime 1: u1 = 7.5 · 10−8, Regime 2: u1 = 7.5 · 10−7, Regime 3:
u1 = 7.5 · 10−6. All other parameters are fixed: d = 2, N = 2 · 105, s1 = s2 = 0.1,
u2 = 2 · 10−5, c2(s1) = 0.16.
successful type-2 mutations arise from successful type-1 mutations (i.e. that do not later
die out). The behavior in the final remaining portion of the parameter space in regime 3
will be the subject of further work.
3 Characterizing the premalignant field
The time between cancer initiation and diagnosis, referred to here as TD, is a subject of
great interest, see e.g. [31] for a review. In general, TD is itself a random variable and
may depend on the natural history of the disease until initiation. However, if we assume
that TD is independent of σ2, then we can characterize the premalignant field at time of
diagnosis, σ2 + TD, by means of the field characterization at time σ2, together with the
distribution of the delay time TD. For this reason, even though the clinically relevant time
is σ2 + TD, we focus here on characterizing the field at σ2. Note that mathematically, this
requires us to condition our analyses upon observing σ2 at some time t, i.e. condition upon
the event {σ2 = t}.
The starting time of the model (t = 0) is assumed to be at the end of tissue development
and the start of the tissue renewal phase. However for some tissues it is difficult to estimate
this time, and thus it may be difficult to ascertain the system time t at the time σ2. In
such cases, it is simple to adapt our analyses to this scenario and treat σ2 as an unknown
quantity, by removing the conditioning on {σ2 = t} and integrating of our results against
12
the density of σ2. The following theorem provides this density in terms of
λ ≡ Nu1 s
1 + s
, (4)
which is the arrival rate of successful type-1 mutations, and
φ(t) ≡ 1
t
∫ t
0
exp
(
−θrd+1
)
dr, (5)
where
θ ≡ u2s¯2γdc
d
d(s1)
d+ 1
, (6)
and s¯2 = s2/(1 + s2).
Theorem 3.1. The waiting time σ2 until birth of the first successful type-2 mutant, has
probability density function
λetλ(φ(t)−1)
(
1− e−θtd+1
)
.
Proof. See (22) in section 7.1.
3.1 Size of the local field at initation
We are first interested in characterizing the size of the local field, i.e. the region of the
premalignant type-1 clone that gives rise to the first successful type-2 clone (see Figure 6).
Following the nomenclature of [32], we note the distinction between two different types of
recurrent tumors: if the recurrence arises from a transformed cell in the premalignant field
that gave rise to the primary tumor, the recurrence is called a second field tumor, see Figure
6A. On the other hand, if the recurrence arises from a premalignant field that is clonally
unrelated to the primary malignancy, it is called a second primary tumor, see Figure 6B.
These two types of recurrent tumors vary in terms of their degree of clonal relatedness
to the primary tumor, and this may have some implications for treatment strategies in
primary vs. recurrent tumors.
We define now Rl(t) to be the radius of the local field at time t, and Xl(t) its corre-
sponding area (Xl = γdR
d
l ). Note that we will use the terminology ‘area’ do describe clone
sizes in all dimensions, and reserve the use of the term ‘volume’ for space-time quantities.
In the following, we are interested in determining the distributions of these two quantities
at time σ2, conditioned on the event {σ2 = t}. In other words, we are looking for the
distributions of (Rl(σ2)|σ2 = t) and (Xl(σ2)|σ2 = t), respectively.
At any given time, each clone produces initiating mutations at a rate proportional to
its area. Hence the probability that clone i (born at time Ti) gives rise to the initiating
mutation at time t is given by the ratio of clone i’s own area,
Xi(t) ≡ γdcdd(s1)(t− Ti)d,
13
Figure 6: Local and distant recurrences. Local (blue) and distant (green) premalignant
fields give rise to second field tumors and second primary tumors (both red), respectively.
In scenario A, there is only one premalignant field (the local field) present at time of cancer
initiation (middle panel), and the recurrence occurs inside the local field. In scenario B,
two unrelated precancerous fields are present at time of initiation (middle panel), and the
recurrence may occur as a second primary tumor in the distant field.
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divided by the total area of type-1 clones present. In other words, the size distribution
of the initiating clone is given by the distribution of a size-biased pick from the different
clones present at the time the initiated mutation arises.
Definition 3.2 (Size-biased pick). Let L1, . . . , Ln be a family of n random variables. A
size-biased pick from L1, . . . , Ln is defined as a random variable L[1] with conditional prob-
ability distribution
P (L[1] = Li|L1, . . . , Ln) = Li/
n∑
j=1
Lj .
The following theorem is the main result of this section and characterizes the size-
distribution of the local field at the time of initiation. This is recognized as a size-biased
pick from the clones present at time t, conditioned on the event {σ2 = t}.
Theorem 3.3. The distribution of the area of the local field at time σ2, conditioned on
{σ2 ∈ dt}, is given by
Pˆ (Xl(σ2) ∈ dx) = Pˆ
(
X[1] ∈ dx
)
=
u2s¯2x
1/d
dγ
1/d
d cd(s1)(1− e−θtd+1)
exp
[
−u2s¯2x d+1d
(d+ 1)γ
1/d
d cd(s1)
]
,
(7)
for x ∈ [0, γdcdd(s1)td].
Proof. See section 7.1.
The distribution of the local field radius follows now easily.
Corollary 3.4. The radius of the local premalignant field at σ2, conditioned on the event
{σ2 = t}, has density
Pˆ (Rl(σ2) ∈ dr) = u2s¯2 γd r
d
cd(s1)(1− e−θtd+1)
exp
[
− u2s¯2γdr
d+1
cd(s1)(d+ 1)
]
,
for r ∈ [0, cd(s1)t].
Note that the distribution of the local field size (7) depends on the rate of successful
mutations u2s¯2 and the growth rate cd(s1), but is independent of λ, the arrival rate of
type-1 mutations. In Figure 7A, we show how the distribution of the local field area (7)
changes with arrival time of the first successful type-2 clone. As expected, the support
of the distribution increases with increasing initiation time, and hence the likelihood of
having a large local field increases substantially. This suggests that that tumors appearing
later have a higher recurrence probability if only the malignant portion is removed during
surgery. The finite support of each probability density function reflects the fact that there
is a hard upper bound on the size of a premalignant field at finite time t in the system.
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Figure 7: Size-distribution of local field. The size-distribution (7) of the local field is
shown for different scenarios, corresponding to the three regimes R1, R2 and R3 illustrated
in Figure 4. A For varying arrival times t; B for varying type-1 mutation rates u1; C for
varying type-2 mutation rates u2; (D) for varying type-1 fitness advantages s1. The non-
varying parameters are held constant at d = 2, N = 2 · 105, u1 = 7.5 · 10−7, u2 = 2 · 10−5,
s1 = s2 = 0.1 and c2(s1) = 0.16.
In Figure 7B,C we illustrate the sensitivity of the size-distribution of the local field to
varying mutation rates u1 and u2, conditioned on observing initiation at the expected time
t = E(σ2). The mutation rates are tuned to vary across parameter Regimes 1, 2, and 3
as described in the previous section. Observe that for lower mutation rates, the local field
size varies widely (and sometimes close to uniformly) over a large range of values, while
elevated mutation rates in both cases signify smaller local fields. For the u1 rate (Figure
7B), an intuitive explanation for this behavior is that as the mutation rate increases, the
system moves towards regimes 2 and 3, in which the premalignant field is comprised of
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an increasing number of independent type-1 patches. The necessary number of man-hours
to the first successful type-2 mutation is absolved faster, and hence the size of the patch
that gives rise to the first successful type-2 decreases accordingly. For u2 (Figure 7C)
on the other hand, an increase in the mutation rate signifies a move towards regime 1:
fewer type-1 clones are required to produce the first successful type-2, and the size of the
type-1 field that yields the first type-2 decreases with increasing u2. Another observation
to note is that the local field size varies across the same range of orders of magnitude as
the mutation rates. This suggests for example, that carcinogen exposure or environmental
causes changing mutation rates by one order of magnitude could result in predicted field
sizes impacted similarly by an order of magnitude.
Finally, we demonstrate the sensitivity of the local field size to the selective advantage
s of mutant cells, see Figure 7D. For a small fitness gain of s = 0.025, the distribution is
peaked at lower field sizes, but as s increases the field size distribution shifts to the right.
High fitness gains are usually associated with an aggressive tumor phenotype, and Figure
7D suggests that such tumors may also be associated with large surrounding premalignant
fields and thus higher recurrence risks.
3.2 Size of the distant field at initiation
Next we are interested in analyzing the size distribution of the distant field at initiation,
which is comprised of premalignant clones that are clonally unrelated to the tumor. Define
the vector of areas of the distant premalignant lesions at time t to be X¯d(t). This vector
holds the areas of all premalignant clones except for the local field clone from which the
tumor arises. Mathematically speaking, the goal of this section is to characterize the law of
X¯d(σ2) conditioned on the event {σ2 = t}. Before stating the main result some additional
notation is needed. First, define the mapping αj(i) as follows:
αj(i) =
{
i, if j > i
i+ 1, if j ≤ i.
Then, we define the random variable X˜i ≡ Xα(i), where
α(i) ≡
M(t)∑
j=1
αj(i)1{X[1]=Xj}.
The distribution of X¯d(σ2) is the joint distribution of (X˜1, . . . , X˜M(σ2)−1), which charac-
terizes the size distribution of the clones in the distant field at time σ2. We obtain the
following result.
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Theorem 3.5. The size-distribution of the distant field clones at time σ2 of the first
successful type-2 mutation, conditioned on {σ2 = t}, is given by
L(X¯d| ∈ dt) =d Pˆ (X˜1 ∈ dx1, . . . , X˜M(t)−1 ∈ dxM(t)−1)
=
1
1− e−λtφ(t)
∞∑
m=1
(λφ(t)t)me−λφ(t)t
m!
m−1∏
i=1
gt(xi),
where gt(x) is defined in (24).
Proof. See section 7.2.
Remark From Theorem 3.5 and Corollary 3.7 below, we see that
L(X¯d|σ2 = t,M(t) = m) =d Pˆ (X˜1 ∈ dx1, . . . , X˜m−1 ∈ dxm−1) =
m−1∏
i=1
gt(xi).
Figure 8 shows how the probability density function of the total distant field size (i.e.
the sum of all distant field patches) changes with increasing mutation rate u1. For a
comparison to the local field size distribution at the same parameter values, we refer to
Figure 7B. We note that in regimes 1 and 2 the total distant field size is on the same order
of magnitude as the local field size, but in regime three the distant field size is significantly
larger than the size of the local field. As will be investigated in more detail below, this
suggests that secondary tumor recurrences for cancer types in regime 3 are much more
likely to stem from the distant field, and thus are more likely to be clonally unrelated to
the primary tumor.
3.3 Number of field patches: evolution until initiation
We next analyze the total number of premalignant lesions over time until tumor initiation.
In particular, the following result holds:
Proposition 3.6. Conditioned on {σ2 = t}, we have that for all ζ ≤ t, the number of field
patches is distributed as a mixture of a Poisson and a shifted Poisson random variable. In
particular,
P (M(ζ) = m|σ2 = t) = p1(t, ζ) λ
m [tφ(t)− (t− ζ)φ(t− ζ)]m
(m)!
e−λ[tφ(t)−(t−ζ)φ(t−ζ)]
+ p2(t, ζ)
λm−1 [tφ(t)− (t− ζ)φ(t− ζ)]m−1
(m− 1)! e
−λ[tφ(t)−(t−ζ)φ(t−ζ)],
where p1(t, ζ) + p2(t, ζ) = 1 and p1(t, ζ) = (1− e−θ(t−ζ)d+1)/(1− e−θtd+1). In particular,
E(M(ζ)|σ2 = t) = λ [tφ(t)− (t− ζ)φ(t− ζ)] + p2(t, ζ).
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Figure 8: The distribution of the total size of the distant field is shown for different
scenarios, corresponding to the three regimes R1, R2 and R3 illustrated in Figure 4 for
varying type-1 mutation rates u1. The non-varying parameters are held constant at d = 2,
N = 2 · 105, u2 = 2 · 10−5, s1 = s2 = 0.1 and c2(s1) = 0.16.
Proof. To prove this result we calculate P (σ2 > t|M(ζ) = m) and then differentiate with
respect to t. Details of the proof are given in section 7.3.
It is interesting to observe that as ζ → t we see that p1(t, ζ) → 0, therefore as ζ gets
closer to time t the process looks more like a shifted Poisson. This is stated in the corollary
below.
Corollary 3.7.
Pˆ (M(t) = m) =
(λ t φ(t))m−1
(m− 1)! e
−tλφ(t), m ≥ 1, (8)
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and Pˆ (M(t) = m) = 0. In particular,
Eˆ(M(t)) = 1 + E(M(t)|σ2 > t) = 1 + λtφ(t), (9)
where E(M(t)|σ2 > t) is discussed in Lemma 7.2.
Using Proposition 3.6, we can study the expected number of field patches of a certain
size over time. Figure 9 shows the temporal dynamics of clone-size distribution in each
regime. In regime 1 the expected number of small clones peaks and then declines as larger
clones begin to dominate (consistent with the notion that a single premalignant clone exists
prior to initiation), whereas in regimes 2 and 3 we see longer coexistence of large and small
clones over time.
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Figure 9: Dynamic clone-size distribution. For each of the three regimes in Figure 5,
the expected number of type-1 clones of sizes comprised in the corresponding intervals Ij
are shown as functions of time up to E(σ2) (expectations are conditioned on {t = E(σ2)}.
The intervals are defined as I1 = [0, 1500), I2 = [1500, 3000), I3 = [3000, 4500) and I4 =
[4500,+∞). Parameter values as in Figure 5.
Remark The result in Proposition 3.6 can be extended to a result about the entire process
{M(r) : 0 ≤ r ≤ t} conditioned on σ2 = t. We present here the joint distribution of the
process at multiple time points, since the proof is similar to Proposition 3.6 we do not
include it. For 0 ≤ r ≤ r′ ≤ t define
φˆ(t; r, r′) =
∫ r′
r
e−θ(t−y)
d+1
dy.
Then for any positive integer `, sequence of time points 0 < r1 ≤ . . . ≤ r` < t and
non-negative integers k1 ≤ k2 ≤ . . . ≤ k` we have that
Pˆ (M(r1) = k1, . . . ,M(r`) = k`)
=
(∑`
i=1
ki − ki−1
φˆ(t; ri−1, ri)
pi + λp`+1
)
1
λ
∏`
j=1
(
λφˆ(t; rj−1, rj)
)kj−kj−1
(kj − kj−1)! e
−λφˆ(t;rj−1,rj),
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where for 1 ≤ i ≤ `+ 1,
pi =
e−θ(t−ri)d+1 − e−θ(t−ri−1)d+1
1− e−θtd+1 ,
r0 = 0, k0 = 0, and r`+1 = t. Note that for each i, 0 < pi < 1 and
∑`+1
i=1 pi = 1, i.e. the
pi’s form a probability vector.
The above joint distribution is rather difficult to parse, so we describe how one would
generate samples of the increments of the process. For 1 ≤ i ≤ `, set Xi = M(ri)−M(ri−1),
then we can generate the values of the vector X1, . . . , X` under the measure Pˆ as follows.
For each 1 ≤ i ≤ ` sample Xi according to a Poisson distribution with mean λφˆ(t; ri−1, ri).
Choose an integer I according to the probability vector (p1, . . . , p`+1), if I = i < ` + 1
replace Xi with Xi + 1.
Note that in contrast to the setting of a Poisson process the random variables X1, . . . , X`
are not independent under Pˆ .
4 Recurrence predictions
Tumor recurrence due to field cancerization poses a substantial clinical problem in many
epithelial cancers [3]. We next aim to use the results of the previous section to develop a
methodology for assessing the risk of tumor recurrence (as well as the likely type of tumor
recurrence) after surgical removal of the primary tumor.
4.1 Local vs. distant field recurrence?
As discussed above, a recurring tumor can either arise in the same premalignant field (a
second field tumor), or it can arise in a clonally unrelated field (second primary tumor).
In this section we characterize the recurrence time distribution for each of these secondary
tumor types, and study how the relative likelihood of local vs. distant recurrence depends
upon parameters of the tissue and cancer type.
To this end, we first study the recurrence time distribution for second field tumors,
which arise from the local premalignant field. Denote the second field recurrence time by
T fR, measured in time units τ starting from τ = 0 at time σ2. The time is reset at the
tumor initiation time σ2, rather than the tumor resection time σ2 + TD, to accommodate
the possibility that a recurrence occurs prior to detection of the primary tumor. Thus if
recurrence occurs at some time τ < TD, then a secondary tumor already exists at the time
of diagnosis of the primary tumor (but may be too small to be detectable). We assume
that the primary tumor node is completely resected once it becomes detectable at time
TD, leaving the surrounding field intact (i.e. there are no excision margins).
At time σ2 a successful type-2 cell arises from a premalignant clone of radius Rl(σ2),
whose distribution is characterized in Corollary 3.4. If Rl(σ2) = r, the incidence rate of
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successful type 2 mutations within this field is given by
η(r, τ) ≡ u2s¯2γd
[
(r + cd(s1)τ)
d − c¯dd(s2) (τ ∧ TD)d
]
, (10)
where c¯d(s2) is the rate of expansion of the malignant cells into the type-1 field. A new
variable c¯d(s2) is introduced to account for the fact that the malignancy may grow both
upwards into the epithelial layer and sideways into the field, depending on the type of
tissue involved (see also Figure 2B).
Corollary 4.1. The probability of a second field tumor having formed before time τ (mea-
sured from σ2), conditioned on {σ2 = t}, is given by
Pˆ (T fR < τ) = 1−
γdu2s¯2
cd(s1)(1− e−θtd+1)
∫ cd(s1)t
0
rd exp
[
− uss¯2γd
cd(s1)(d+ 1)
rd+1 −
∫ τ
0
η(r, s)ds
]
dr.
In particular, Pˆ (T fR < TD) is the probability that smaller, possibly undetectable second field
tumors exist at the time of diagnosis.
Proof. See section 7.4.
In Figure 10A the cumulative distribution function of T fR as calculated in Corollary
4.1 is shown, for varying values of type-2 mutation rates u2. As one might expect, higher
mutation rates yield a decreased time to recurrence (the curves shift to the left for increasing
u2). However, considering that the size of the premalignant field at initiation of the primary
tumor is inversely proportional to the mutation rate u2, see Figure 10B, the decrease in
time to recurrence is a priori not obvious: a bigger precancer field increases the chance of
fast recurrence. This example illustrates how a quantitative model enables us to assess the
relative importance of competing aspects of the system - in this case, the impact of larger
premalignant field versus higher mutation rates on recurrence likelihood.
If the recurrence does not take place in the local field giving rise to the first successful
type-2 clone, then it either arises from one of the type-1 clones already present at time of
initiation (i.e. the distant field), or it arises in a type-1 clone formed after initiation. In
the latter case, the waiting time is again distributed as σ2, and hence we focus here on the
distribution of the waiting time T pR, defined as the time from σ2 until a second primary
tumor arises from the distant field already existing at σ2. We have the following result.
Corollary 4.2. The probability that the distant field at the time of initiation gives rise to
a second primary tumor by time τ (measured from σ2), conditioned on {σ2 = t}, is given
by
P (T pR > τ |σ2 = t) = exp [−λtφ(t) (1− dγdΦ(τ, t))]
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Figure 10: Time to local recurrence. A The cumulative distribution function of the
time to recurrence of a second field tumor is shown for three different scenarios, corre-
sponding to u2 = 2 · 10−3 (Regime 1), u2 = 2 · 10−5 (Regime 2) and u2 = 2 · 10−3 (Regime
2/3), respectively. The remaining parameters are d = 2, N = 2 · 105, u1 = 7.5 · 10−7,
s1 = s2 = 0.1, t = E(σ2). B Schematic of the relative initiation times of the primary
tumor (yellow) and sizes of the local fields (blue), for the three scenarios in panel A. The
numerical values for expected initiation time and local field size are: (a) E(σ2) = 123,
Eˆ(Rl) = 8; (b) E(σ2) = 281, Eˆ(Rl) = 31; (c) E(σ2) = 474, Eˆ(Rl) = 55.
where
Φ(τ, t) =
∫ ∞
0
exp
(
−
∫ τ
0
η (r, s) ds
)
rd−1gt(rdi γd)dr,
and gt is defined in (24).
Proof. See section 7.5.
Thanks to the results in this section, it is now possible to evaluate the probability of
local versus distant tumor recurrences in each parameter regime. Corollary 4.1 explicitly
provides the probability density function Pˆ (T fR ∈ dτ), which is the probability that a second
field tumor arises at time τ from the same field that gave rise to the primary tumor. To
obtain the corresponding probability density function for recurrence as a second primary
tumor, we have to consider recurrences due to distant field lesions that have arisen before
and after σ2. While Corollary 4.2 characterizes the recurrence risk due to distant lesions
already present at initiation, the time to a successful second primary tumor from a distant
field not yet present at initiation is distributed as σ2, see Theorem 3.1. Therefore, the
distribution of interest is that of T˜ pR = min{T pR, σ2}, which is the time of the first distant
recurrence event.
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In Figure 11 we study how the comparison between the probability density functions
of T fR (second field tumor, local) and T˜
p
R (second primary tumor, distant) varies in regimes
1, 2 and 3. The likelihood of local vs. distant recurrences depends strongly upon both the
timing and parameter regime of the system In regime 1, local recurrence is significantly
more likely overall, but at late times the probability of distant recurrences is slightly higher
than for local recurrences. In contrast, in regimes 2 and 3 the overall probability of local
and distant recurrences are comparable. However, in regime 2, at early times distant field
recurrences are more likely, whereas the opposite is true at later times. The same observa-
tion, but even more pronounced, holds in regime 3. These results show that fundamental
tissue parameters (e.g. renewal rate, size, mutation rate) could be used to provide insights
into the timing and clonal relatedness of tumor recurrences, and suggest a new strategy
for prognosis prediction and risk stratification.
5 Conclusions and outlook
In this study we performed a quantitative analysis of the cancer field effect by means
of a spatial stochastic model of cancer initiation, which had previously been introduced
in [26]. Based on this model, we investigated various characteristics of premalignant fields
at the time of tumor initiation. In particular, we derived the size-distributions of the
local field (the premalignant lesion that gives rise to the tumor) and the distant field (the
premalignant lesions that are unrelated to the primary tumor). We calculated the dynamic
clone size distribution at times leading up to initiation, and derived the probability density
functions of local and distant recurrence times. Finally, we compared the relative likelihood
of second field versus second primary tumors, and demonstrated how the clonal relatedness
between primary and recurrent tumors depends explicitly upon tissue and cancer type
parameters.
Using an example set of parameters in two space dimensions (which is appropriate for
describing the cancer initiation process in the basal layer of a stratified epithelium), we
found that lower mutation rates (such as in regime 1) were associated with larger local
field sizes, whereas higher mutation rates (regimes 2 and 3) led to smaller local fields.
We also found that higher mutation rates resulted in larger distant fields, while more
aggressive cancers (high selective advantage) led to larger local fields at diagnosis. Finally,
we investigated the risk of recurrence after surgical resection of the malignant portion, and
found that for low mutation rates (regime 1), local recurrence is much more likely, whereas
for larger mutation rates (regimes 2 and 3), the overall probability of local and distant
recurrences are comparable. However, in regimes 2 and 3, early recurrences are more likely
to be a second primary tumor, whereas the late recurrences are more likely to be second
field tumors.
One important limitation of our approach is that the model captures a specific sequence
of genetic alterations with specified ui and si, and does currently not allow for permuta-
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Figure 11: Local vs. distant recurrence. A For each of the three regimes in Figure
5, we show: the distribution of time to local recurrence Pˆ (T fR ∈ dτ), and the distribution
of time to distant recurrence Pˆ (T˜ pR ∈ dτ). The distribution of T fR is given in Corollary
4.1 and we set T˜ pR = min{T pR, σ2} to account both for contributions from type-1 clones
already existing at σ2 as well as contributions from type-1 clones born after σ2 (for which
time to recurrence is distributed as σ2). Expected times to recurrence: Eˆ(T
f
R) = 81 and
Eˆ(T˜ pR) = 733 (Regime 1); Eˆ(T
f
R) = 98 and Eˆ(T˜
p
R) = 86 (Regime 2); Eˆ(T
f
R) = 149 and
Eˆ(T˜ pR) = 34 (Regime 3). The parameter values are as in Figure 5.
tions of genetic events and divergent pathways. Nevertheless, our model may provide a
useful framework for comparing different biological hypotheses and disentangling divergent
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genetic pathways among cancer subtypes. In particular, it enables us to predict differences
in observable dynamics such as initiation times and prognoses between different molecular
models. Such an approach could help elucidating the sequence of genetic events during car-
cinogenesis, and will be the subject of future work. Another limitation of our framework is
that we have assumed a static, uniform microenvironment within the tissue. The local mi-
croenvironment is in reality determined by a variety of time- and space-dependent factors
such as glucose, oxygen, growth factors, drugs and cytokine concentrations. In addition
to impacting the growth and mutation rates of cells within the tissue, the local microen-
vironment is increasingly being recognized as playing an important role in carcinogenesis
through stromal signaling. Lastly, in order to apply this framework to specific cancer types
(as will be done in a follow-up work), appropriate parameter values for the model need to
be determined. Literature estimates can usually be obtained for tissue parameters such as
compartment size and tissue regeneration rates. In addition, baseline estimates for point
mutation rates are available, usually down to an uncertainty of 1-2 orders of magnitude.
Estimates of the relative selective advantage conferred by each mutation are more difficult
to ascertain; however some estimates can be obtained from proliferation marker staining
and in vitro studies.
In summary, the analyses performed in this work contribute towards a quantitative
understanding of how organ-specific physiological parameters (e.g. number of proliferative
cells, tissue renewal rates), as well as pathway-specific parameters (e.g. cellular mutation
rate, selective advantages conferred by each oncogenic mutation) influence the process of
field cancerization and the associated risks of recurrence. We demonstrated that tumor
recurrence dynamics and premalignant field characteristics are strongly dependent upon
these parameters, which vary across different tissue and cancer types. Once properly cali-
brated for a specific tissue and cancer type, the proposed methodology can potentially be
used to provide insights into key prognostic factors such as risk of multifocal lesions and
tumor recurrence, surveillance guidelines, and treatment design. For example, we are able
to assess the likelihood and timing of local versus distant recurrences after surgical resec-
tion. Since this distinction provides information on the level of clonal relatedness between
primary and recurrent tumors, the model predictions may provide insights into whether
treatment strategies effective for primary tumors will be useful for recurrent tumors in
particular cancer types. In addition, our methodology can be utilized to assess the relative
benefits of surgical excision margins (removal of apparently healthy tissue surrounding tu-
mors), and to help determine the minimal margins necessary to prevent recurrence in each
tissue type. We consider the work presented here as a proof of concept: a mathematical
framework which, once properly calibrated, refined and validated, may provide a useful
tool in molecular epidemiology (e.g. mechanistic modeling of carcinogen exposure), as well
as the development of probabilistic models for personalized treatment approaches.
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7 Appendix: Proofs
7.1 Proof of Theorem 3.3
To prove Theorem 3.3, we first need a few new definitions and preliminary results. Define
V (t) to be the random total space-time volume covered by successful type-1 families until
time t,
V (t) =
M(t)∑
i=1
γdc
d
d(s1)
(t− Ti)d+1
d+ 1
, (11)
where Ti represents the arrival time of the i-th family, and M(t) is the total number of
successful arrivals by time t, which is a Poisson process with rate λ. Let VEt represent the
space-time volume conditioned on the event
Et(t1, . . . , tm) ≡ {M(t) = m,T1 ∈ dt1, . . . Tm ∈ dtm},
where 0 < t1 < · · · < tm < t. In other words,
VEt ≡
γdc
d
d(s1)
d+ 1
m∑
i=1
(t− ti)d+1. (12)
For ease of notation we replace VEt(t1,...,tn) with the more compact version VEt . Since
E[V (t)] = E[E[V (t)|M(t)]] and the conditioned process is a compound Poisson process,
we obtain that
E[V (t)] =
∞∑
m=0
P (M(t) = m)
mγdc
d
d(s1)
d+ 1
E[(t− Ti)d+1] = λγdcdd(s1)
td+2
(d+ 2)(d+ 1)
.
Similarly, we define A(t) to be the total area of clones covered by successful type-1 families
at time t,
A(t) ≡
M(t)∑
i=1
γdc
d
d(s1)(t− Ti)d, (13)
and we define AEt to be this quantity conditioned on Et(t1, . . . , tm),
AEt ≡
m∑
i=1
γdc
d
d(s1)(t− ti)d. (14)
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Note that
E[A(t)] =
∞∑
m=0
P (M(t) = m)mγdc
d
d(s1)E[(t− Ti)d] = λγdcdd(s1)
td+1
d+ 1
. (15)
By considering the space-time volume of type-1 clones we can calculate P (σ2 > t|Et(t1, . . . , tm)
and P (σ2 > t|M(t) = m). Combining these two formulas and using Bayes rule we get the
following result for the joint distribution of the arrival times of successful type-1 mutations,
conditioned on the total number of mutations by time t.
Lemma 7.1. Conditioned on {σ2 > t} and {M(t) = m}, the arrival times of successful
type-1 clones (T1, . . . , Tm) are distributed as order statistics of iid random variables as
follows:
P (T1 ∈ dt1, . . . , Tm ∈ dtm|σ2 > t,M(t) = m) = m!
tmφ(t)m
m∏
i=1
e−θ(t−ti)
d+1
where 0 < t1 < · · · < tm < t.
Proof. The arrival process of successful type-1 mutations is represented by M(·), which is
a Poisson process with rate λ = Nu1s1/(1 + s1) and arrival times T1, T2, . . .. Then for any
t > 0 and sequence 0 < t1 < · · · < tm < t we have that
P (Et(t1, . . . , tm)) = λme−λt. (16)
Since
P (σ2 > t|Et(t1, . . . , tm)) = exp(−u2s¯2VEt), (17)
we find using Bayes’ rule
P (σ2 > t, Et(t1, . . . , tm)) = λme−λt exp(−u2s¯2VEt).
It follows then that
P (T1 ∈ dt1, . . . , Tm ∈ dtm|σ2 > t,M(t) = m) = P (σ2 > t, Et(t1, . . . , tm))
P (σ2 > t|M(t) = m)P (M(t) = m)
=
λme−λt exp (−u2s¯2VEt)
P (σ2 > t|M(t) = m)e−λt(λt)m/m!
=
m!
tm
exp (−u2s¯2VEt)(
E exp
(−u2s¯2γdcdd(s1)(t− T )d+1/(d+ 1)))m
= m!
m∏
i=1
(
1
t
)
exp
(−u2s¯2γdcdd(s1)(t− ti)d+1/(d+ 1))
E exp
(−u2s¯2γdcdd(s1)(t− T )d+1/(d+ 1)) ,
where T is a uniform random variable on [0, t]. .
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The distribution in Lemma 7.1 is an exponential twist of the uniform distribution.
Note that if the conditioning was placed on the set {σ2 = t} instead of {σ2 > t}, then
the conditional distribution would no longer have product form because of the term ddtVEt ,
and the arrival times would not be the order statistics from an iid collection of random
variables.
Next, we show that the random variable M(t) is Poisson if conditioned on {σ2 > t}.
Lemma 7.2. Conditioned on {σ2 > t}, M(t) =d Pois (λtφ(t)) .
Proof. First we note that
P (σ2 > t) =
∞∑
m=0
1
m!
∫
[0,t]m
P (σ2 > t|Et(t1, . . . , tm))P (Et(t1, . . . , tm))dt1 . . . dtm
=
∞∑
m=0
1
m!
∫
[0,t]m
exp (−uss¯2VEt)λme−λtdt1 . . . dtm
=
∞∑
m=0
1
m!
tmλm e−λt
(
1
t
∫ t
0
exp
(
−u2s¯2γdc
d
d(s1)(t− r)d+1
d+ 1
)
dr
)m
=
∞∑
m=0
(tλφ(t))m
m!
e−λt = etλ(φ(t)−1).
(18)
From this, we find using Bayes’ rule
P (Et(t1, . . . , tm)|σ2 > t) =P (σ2 > t|Et(t1, . . . , tm)P (Et(t1, . . . , tm))
P (σ2 > t)
=
λme−λt exp(uss¯2VEt)
etλ(φ(t)−1)
,
(19)
and hence
P (M(t) = m|σ2 > t) = 1
m!
∫
[0,t]m
P (Et(t1, . . . , tm)|σ2 > t)dt1 . . . dtm
=e−λtφ(t))
(tλφ(t))m
m!
.
.
For subsequent considerations, it will be useful to define the two conditional probability
measures Pˆ (·) = P (·|σ2 = t) and P˜ (·) = P (·|σ2 > t), and their corresponding expected
values, Eˆ(·) = E(·|σ2 = t) and E˜(·) = E(·|σ2 > t), respectively. In particular, we can
compute the Radon-Nikodym derivative between these two measures.
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Lemma 7.3. The Radon-Nikodym derivative of Pˆ with respect to P˜ is given by
dPˆ
dP˜
=
AEtu2s¯2
λ(1− e−θtd+1) . (20)
Proof. First, note that
P (Et(t1, . . . , tm)|σ2 = t) = P (Et(t1, . . . , tm))P (σ2 = t|Et(t1, . . . , tm))
P (σ2 = t)
. (21)
By differentiating (17) and (18) we obtain
P (σ2 = t|Et(t1, . . . , tm)) = u2s¯2AEt exp(−u2s¯2VEt)
and
P (σ2 ∈ dt) = − d
dt
etλ(φ(t)−1) = λ
(
1− e−θtd+1
)
etλ(φ(t)−1). (22)
Hence (21) becomes
P (Et(t1, . . . , tm)|σ2 = t) = λme−λt u2s¯2AEt exp(−u2s¯2VEt)
λetλ(φ(t)−1)(1− e−θtd+1) ,
and comparing this to (19) yields the desired result.
Recall now that M(t) is the number of successful type-1 mutations that have arrived
by time t, and we denote their arrival times by T1, . . . , TM(t). At time t, the area of a clone
created at time r < t is γdc
d
d(s1)(t − r)d, and hence the area of the i-th clone at time t is
given by the random variable
Xi(t) ≡ γdcdd(s1)(t− Ti)d.
Using the above results together with definition 3.2 of a size-biased pick we can now prove
Theorem 3.3.
Proof of Theorem 3.3. Using basic properties of conditional expectations and Definition
3.2 we find
Pˆ (X[1] ∈ dx) = Eˆ
[
Pˆ (X[1] ∈ dx|X1, . . . , XM(t),M(t))
]
= Eˆ
M(t)∑
i=1
Xi1{Xi∈dx}
SM(t)
 = ∞∑
m=1
Eˆ
[
m∑
i=1
Xi1{Xi∈dx}
Sm
1{M(t)=m}
]
,
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where Sm = X1 + . . .+Xm. Using the Radon-Nikodym derivative (20) we can rewrite this
as
=
∞∑
m=1
E˜
1{M(t)=m}u2s¯2
λ(1− e−θtd+1)
(
m∑
i=1
Xi1{Xi∈dx}
Sm
)
m∑
j=1
Xj

=
u2s¯2
λ(1− e−θtd+1)
∞∑
m=1
E˜
[
1{M(t)=m}
m∑
i=1
x1{Xi∈dx}
]
=
xu2s¯2
λ(1− e−θtd+1)
∞∑
m=1
E
[
m∑
i=1
1{Xi∈dx}|M(t) = m,σ2 > t
]
P (M(t) = m|σ2 > t)
=
xu2s¯2
λ(1− e−θtd+1)P (X1(t) ∈ dx|M(t) = m,σ2 > t)E [M(t)|σ2 > t] ,
(23)
where we have used the fact that P (X1(t) < x|M(t) = m,σ2 > t) is independent of m,
which we will show below. Using Lemma 7.1 and differentiating the cumulative distribution
function
P (X1(t) < x|M(t) = m,σ2 > t) = P
(
T1 > t−
(
x
γdc
d
d(s1)
)1/d ∣∣∣M(t) = m,σ2 > t) ,
we determine that
P (X1(t) ∈ dx|M(t) = m,σ2 > t) = x
1/d−1
dγ
1/d
d cd(s1)tφ(t)
exp
[
−u2s¯2x d+1d
(d+ 1)γ
1/d
d cd(s1)
]
≡ gt(x)
(24)
for x ∈ [0, γdcdd(s1)td]. Note that (24) is indeed independent of m. From Lemma 7.2 it
follows that
E [M(t)|σ2 > t] = λtφ(t),
and combined with (23) and (24) this yields the desired result.
7.2 Proof of Theorem 3.5
Using Definition 3.2 of a size-biased pick we find
Pˆ (X˜1 ∈ dx1, . . . , X˜M(t)−1 ∈ dxM(t)−1)
= Eˆ[Pˆ (X˜1 ∈ dx1, . . . , X˜M(t)−1 ∈ dxM(t)−1|X1, . . . , XM(t),M(t))]
= Eˆ
M(t)∑
j=1
Xj
SM(t)
M(t)−1∏
i=1
1{Xαj(i)∈dxi}

=
u2s¯2
λ(1− e−θtd+1)
∞∑
m=1
P (M(t) = m|σ2 > t)E
 m∑
j=1
Xj
m−1∏
i=1
1{Xαj(i)∈dxi}
∣∣∣σ2 > t,M(t) = m
 ,
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where the final equality follows from the same sequence of arguments as used in the proof
of Theorem 3.3. Next, we note that
E[Xj(t)|σ2 > t,M(t) = m] =
∫ ∞
0
xP (Xj(t) ∈ dx|M(t) = m,σ2 > t) =
∫ ∞
0
x gt(x)dx
=
∫ γdcdd(s1)td
0
x1/d
dγ
1/d
d cd(s1)φ(t)t
exp
[
−u2s¯2x d+1d
(d+ 1)γ
1/d
d cd(s1)
]
dx
=
1
φ(t)tu2s¯2
[
1− exp
(
−u2s¯2γdc
d
d(s1)t
d+1
d+ 1
)]
,
and
m∑
j=1
E
[
Xj
m−1∏
i=1
1{Xαj(i)∈dxi}
∣∣∣σ2 > t,M(t) = m] = m∑
j=1
E[Xj |σ2 > t,M(t) = m]
m−1∏
i=1
gt(xi).
Together with Lemma 7.2 the result follows.
7.3 Proof of Proposition 3.6
First, we use Bayes’ rule to find
P (Eζ(t1, . . . , tm)|σ2 = t) = P (σ2 ∈ dt|Eζ(t1, . . . , tm))P (Eζ(t1, . . . , tm))
P (σ2 ∈ dt) . (25)
Since P (σ2 ∈ dt) is given in (22) and P (Eζ(t1, . . . , tm)) = λme−λζ , it remains to calculate
P (σ2 ∈ dt|Eζ(t1, . . . , tm)). It is easy to see that
P (σ2 > t|Eζ(t1, . . . , tm)) = exp (−u2s¯2VEt) q(ζ, t), (26)
where q(ζ, t) is the probability that a type-2 mutation arises in a clone that is born in the
interval (ζ, t). We find
q(ζ, t) =E
[
e−θ
∑M(t−ζ)
i=1 (t−Ti)d+1
]
=E
[
E
[
e−θ
∑M(t−ζ)
i=1 (t−Ti)d+1
∣∣∣M(t− ζ)]]
=E
[
φ(t− ζ)M(t−ζ)
]
= eλ(t−ζ)(φ(t−ζ)−1),
where the last expression is the generating function for the Poisson process. Together with
(26) this yields now
P (σ2 ∈ dt|Eζ(t1, . . . , tm)) =− d
dt
P (σ2 > t|Eζ(t1, . . . , tm))
=eλ(t−ζ)(φ(t−ζ)−1)e−u2s¯2VEt
[
uss¯2AEt + λ
(
1− e−θ(t−ζ)d+1
)]
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Together with (22) and (16), we find now
P (Eζ(t1, . . . , tm)|σ2 = t) = λm−1 e
−λ[tφ(t))−(t−ζ)φ(t−ζ)](
1− e−θtd+1) e−u2s¯2VEt
[
uss¯2AEt + λ
(
1− e−θ(t−ζ)d+1
)]
,
and hence performing the integration in
Pˆ (M(ζ) = m) =
∫
[0,ζ]m
1
m!
P (Eζ(t1, . . . , tm)|σ2 = t)dt1 . . . dtm
yields the desired result.
7.4 Proof of Corollary 4.1
Pˆ (T fR > τ) =P
(
T fR > τ |σ2 = t
)
=
∫ cd(s1)t
0
P (T fR > τ,Rl(σ2) ∈ dr|σ2 = t)dr
=
∫ cd(s1)t
0
P (T fR > τ |Rl(σ2) ∈ dr, σ2 = t)P (Rl(σ2) ∈ dr|σ2 = t)dr,
where Rl(t) is the radius of the local field surrounding the tumor at time t. The result
follows from
P (T fR > τ |Rl(σ2) ∈ dr, σ2 = t) = exp
(
−
∫ τ
0
η(r, s)ds
)
(27)
and the conditional density of Rl(σ2) in Corollary 3.4.
7.5 Proof of Corollary 4.2
First, we note that
P (T pR > τ |M(t) = m,σ2 = t)
=
∫
Rm−1+
P
(
T pR > τ |R˜1 ∈ dr1, . . . , R˜m−1 ∈ drm−1,M(t) = m,σ2 = t
)
· · ·
· · ·P
(
R˜1 ∈ dr1, . . . , R˜m−1 ∈ drm−1|M(t) = m,σ2 = t
)
,
(28)
where R˜i are the radii of the distant field clones, corresponding to their respective areas
X˜i defined in Section 3.2. Recalling the definition of η in (10), we find
P
(
T pR > τ |R˜1 ∈ dr1, . . . , R˜m−1 ∈ drm−1,M(t) = m,σ2 ∈ dt
)
= exp
(
−
m−1∑
i=1
∫ τ
0
η (ri, s) ds
)
.
(29)
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Recalling the Radon-Nikodym derivative dPˆ /dP˜ from Lemma 7.3, it is straight-forward to
verify that
dP (t1, . . . tm|M(t) = m,σ2 = t)
dP (t1, . . . tm|M(t) = m,σ2 > t) =
dPˆ
dP˜
P (M(t) = m|σ2 > t)
P (M(t) = m|σ2 = t) =
AEtu2s¯2tφ(t)
m(1− e−θtd+1) ,
which allows us to derive the following expression (proceeding as in the proof of Corollary
3.5),
P
(
X˜1 ∈ dx1, . . . , X˜m−1 ∈ dxm−1|M(t) = m,σ2 = t
)
=
m−1∏
i=1
g(xi)dxi.
Switching from the clone-areas X˜i back to the corresponding radii R˜i, we find
P
(
R˜1 ∈ dr1, . . . , R˜m−1 ∈ drm−1|M(t) = m,σ2 = t
)
= (d γd)
m−1
m−1∏
i=1
rd−1i g(r
d
i γd)dri
From this, (29) and (28) we find
P
(
T pR > τ |M(t) = m,σ2 = t
)
= (d γd Φ(τ, t))
m−1 , (30)
Finally, using Lemma 7.2,
Pˆ (T pR > τ) =
∞∑
m=1
P
(
T pR > τ |M(t) = m,σ2 = t
)
Pˆ (M(t) = m)
= exp (−λtφ(t) (1− dγdΦ(τ, t)))
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